Sanjivani Paranteral
219.00
+20.75(+10.47%)
Market Cap₹- Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D+10.47%
1M+3.16%
6M-12.24%
1Y-26.21%
5Y+2,053.39%
View Company Insightsright
More news about Sanjivani Paranteral
18Aug 25
Sanjivani Parenteral Reports 8.9% Revenue Growth in Q1, Pune Facility Set for Commercial Production
Sanjivani Parenteral Limited, a WHO-GMP certified pharmaceutical company, reported Q1 revenue growth of 8.9% YoY to INR 17.90 crores. EBITDA increased by 10.8% to INR 2.70 crores, with margins improving to 15.00%. The company maintains a 73.70%-26.30% export-domestic revenue mix, exporting to over 25 countries. Their new Pune facility is expected to begin commercial production by early September. The company added 8 new products in Q1 and Q2 combined and is focusing on expanding in LATAM and French-speaking African markets. Despite logistical challenges, management remains optimistic, providing a full-year revenue guidance of INR 75-80 crores.
12Aug 25
Sanjivani Paranteral Reports 8.9% Revenue Growth in Q1 FY26, Driven by Strong Injectables Performance
Sanjivani Paranteral Limited reported an 8.9% year-over-year revenue growth to ₹178.90 crore for Q1 FY26. EBITDA increased by 10.8% to ₹26.80 crore, while PAT grew marginally by 1.0% to ₹17.30 crore. The injectables segment showed robust growth of 47.1%, but the oral segment declined by 11.1% due to shipment challenges. Exports constituted 73.7% of total revenue, with core markets in CIS, Middle East & Africa, and Latin America contributing significantly. The company remains focused on R&D and expanding its product portfolio to drive future growth.
Sanjivani Paranteral
219.00
+20.75
(+10.47%)
1 Year Returns:-26.21%
Industry Peers
Windlas Biotech
790.15
(+0.55%)
Jeena Sikho Lifecare
699.20
(+0.52%)
Blue Jet Healthcare
554.80
(-2.56%)
Abbott
28,850.00
(-0.14%)
Sunrest Lifescience
42.05
(-2.21%)
Zenith Drugs
54.60
(+2.25%)
Pfizer
5,001.00
(+0.57%)
FDC
414.10
(+0.24%)